Sanofi and Seagen Collaborate to Develop and Commercialize ADC Targeting Cancer
Shots:
- Sanofi and Seagen collaborated to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets
- The companies will co-fund global development activities and will equally share the profits. Seagen will receive the payment for each of the three targets once they are selected
- The collaboration will utilize Sanofi’s monoclonal antibody (mAb) technology and Seagen’s ADC technology
Ref: Sanofi | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
